Selenium-Loaded Calcium Phosphate with Long-Term and Curative Dosage Drug Release for Post-Surgical Osteosarcoma Management and Osteogenesis.

Yang Yan, Yue Chen, Danjie Meng, Shidong Liu, Yuxin Wan, Zhenze Xie, Dong Xu, Chang Du

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang YanZhejiang Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.

Yue ChenZhejiang Provincial Clinical Research Center for Oral Diseases, Stomatology Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.

Danjie MengDepartment of Pediatric Dentistry, Stomatology Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.

Shidong LiuDepartment of Pathology, Stomatology Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.

Yuxin WanDepartment of Biomedical Engineering, School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China.

Zhenze XieDepartment of Biomedical Engineering, School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China.

Dong XuDepartment of Biomedical Engineering, School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China.

Chang DuDepartment of Biomedical Engineering, School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China.

Funding

111 project B13039

6 · The paper itself

Abstract

Although neoadjuvant chemotherapy is widely used after osteosarcoma (OS) surgery, suboptimal chemotherapy accelerates OS recurrence, and postoperative bone repair remains challenging. Here, we report a selenium-loaded biomimetic calcium phosphate (Se@BioCaP) to provide a long-term therapeutic-dose release for postoperative OS treatment. Sodium selenite was incorporated into a biomimetic calcium phosphate (BioCaP) via a wet biomimetic mineralization protocol. The release kinetics of Se@BioCaP achieved a transition from non-Fickian transport to Fickian diffusion, delivering sustained cytotoxic concentrations under acidic, tumor-like conditions while maintaining biocompatibility with osteoblasts (OBs) under physiological conditions. The reduction in OS cell viability was associated with the disruption of redox homeostasis, including the downregulation of key antioxidant enzymes (SOD2 and GPx1), increased reactive oxygen species (ROS), and acidic vesicular organelle (AVO) formation. Notably, Se@BioCaP200 extracts maintained in vitro anticancer and pro-osteogenic activity at day 42, while antibacterial activity was maintained through day 42. These findings suggest that Se@BioCaP may be a promising candidate for postoperative OS management.

Indexed as

Bone NeoplasmsCalcium PhosphatesOsteogenesisOsteosarcomaSeleniumAntineoplastic AgentsCell Line, TumorCell SurvivalDrug LiberationHumansOsteoblastsReactive Oxygen SpeciesAntineoplastic Agentscalcium phosphateCalcium PhosphatesReactive Oxygen SpeciesSeleniumantibacterial activitybone regenerationcalcium phosphatecontrolled releaseosteosarcomaredox homeostasisselenite

Identifiers

PMID42511751

DOI10.3390/ijms27146408

PMCPMC13409978

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.